Alterity Therapeutics Files 6-K, Incorporates into S-8/F-3 Filings
Ticker: PRNAF · Form: 6-K · Filed: Jul 1, 2024 · CIK: 1131343
| Field | Detail |
|---|---|
| Company | Alterity Therapeutics Ltd (PRNAF) |
| Form Type | 6-K |
| Filed Date | Jul 1, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, securities-offering, registration-statement
Related Tickers: ATH
TL;DR
Alterity Therapeutics (ATH) filed a 6-K, incorporating it into existing S-8/F-3 filings. Notification on unquoted securities included.
AI Summary
Alterity Therapeutics Limited filed a Form 6-K on July 1, 2024, for the month of June 2024. This report is being incorporated by reference into several of the company's existing Registration Statements on Form S-8 and Form F-3. The filing includes Exhibit 99.1, a notification regarding unquoted securities for ATH.
Why It Matters
This filing indicates ongoing corporate actions and regulatory compliance, potentially affecting the trading of Alterity's securities and its ability to issue new ones under existing registration statements.
Risk Assessment
Risk Level: low — The filing is a routine report and incorporation by reference, not indicating new material adverse events or significant financial changes.
Key Players & Entities
- Alterity Therapeutics Limited (company) — Registrant
- ATH (company) — Ticker symbol for Alterity Therapeutics
- Form S-8 (document) — Registration Statement type
- Form F-3 (document) — Registration Statement type
- Exhibit 99.1 (document) — Included exhibit
FAQ
What is the purpose of incorporating this 6-K into existing registration statements?
Incorporating the 6-K into Form S-8 and Form F-3 registration statements allows the company to update or supplement information related to the securities covered by those statements without filing entirely new registration statements.
What specific information is contained in Exhibit 99.1?
Exhibit 99.1 is a notification regarding unquoted securities for ATH.
What is the filing date of this Form 6-K?
This Form 6-K was filed on July 1, 2024.
What period does this Form 6-K report cover?
This Form 6-K reports for the month of June 2024.
What is the principal executive office address of Alterity Therapeutics Limited?
The principal executive office is located at Level 14, 350 Collins Street, Melbourne, Victoria 3000, Australia.
Filing Stats: 190 words · 1 min read · ~1 pages · Grade level 12 · Accepted 2024-07-01 06:19:44
Filing Documents
- ea0208692-6k_alterity.htm (6-K) — 14KB
- ea020869201ex99-1_alterity.htm (EX-99.1) — 71KB
- ex99-1_001.jpg (GRAPHIC) — 1KB
- 0001213900-24-057457.txt ( ) — 88KB
From the Filing
OF FOREIGN PRIVATE ISSUER SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-163 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Alterity Therapeutics Limited (Name of Registrant) Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia (Address of Principal Executive Office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073 , 333-248980 and 333-228671 ) and our Registration Statements on Form F-3 (Files No. 333-274816 , 333-251647 , 333-231417 and 333-250076 ) ALTERITY THERAPEUTICS LIMITED (a development stage enterprise) The following exhibits are submitted: 99.1 Notification regarding unquoted securities - ATH 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Alterity Therapeutics Limited By: /s/ Geoffrey P. Kempler Geoffrey P. Kempler Chairman Date: June 28, 2024 2